Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Renal Cell 27Neoplasms 9Neoplasm Metastasis 9Breast Neoplasms 9Kidney Neoplasms 6Prostatic Neoplasms 4Gastrointestinal Stromal Tumors 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplasms by Histologic Type 3Melanoma 3Liver Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Primary Myelofibrosis 2Neuroendocrine Tumors 2Neoplasms, Glandular and Epithelial 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Site 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Digestive System Neoplasms 2Clear-cell metastatic renal cell carcinoma 2

Interventions

pembrolizumab 3Nivolumab 3Ipilimumab 3Cyclophosphamide 3Radiosurgery 2MART-1 Antigen 2CTLA-4 Antigen 2ulixertinib 1sotrastaurin 1siremadlin 1relatlimab 1pentetreotide 1oblimersen 1incomplete Freund's adjuvant 1fotemustine 1fludarabine phosphate 1fludarabine 1entrectinib 1defactinib 1binimetinib 1benzamide 1aldesleukin 1aflibercept 1Valacyclovir 1Toll-Like Receptor 1 1TYRP1 protein, human 1Sunitinib 1Standard of Care 1RO5126766 1RNA, Messenger 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Uveal Melanoma × Sunitinib × Clear all
NCT00482911 2017-03-27

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
12 enrolled 10 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡